Research progress of interleukin-37 in inflammatory diseases of bone and joint

doi:10.3877/cma.j.issn.1674-134X.2019.02.012

Abstract

Abstract:

Interleukin-37, known as one of IL-1 family members, was a recently found with broadly function in reducing innate inflammation as well as acquired immune responses. There are five variants in its transcripts (IL-37a-e), by which IL-37b is the focus of the studies. Important effect of IL-37 is found in the development of Inflammatory diseases of bone and joint. However, how it regulates in innate inflammation and acquired immune responses is not completely understood. To sum up theoretical basis for the pathogenesis, classification and diagnosis of inflammatory diseases of bone and joint and to provide new ideas for the application of IL-37 in the diagnosis and treatment of inflammatory diseases of bone and joint, this article reviewed the biological characteristics and signaling pathways of IL-37 and summary its researches in inflammatory diseases of bone and joint.

Key words: Interleukins, Osteitis, Arthritis, rheumatoid, Spondylitis, ankylosing, Arthritis, gouty, Osteoarthritis

Zhijian Yang, Qi Li. Research progress of interleukin-37 in inflammatory diseases of bone and joint[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2019, 13(02): 200-205.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2019.02.012

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2019/V13/I02/200

References 37

[1]	Nold MF, Nold-Petry CA, Zepp JA, et al. IL-37 is a fundamental inhibitor of innate immunity[J]. Nat Immunol, 2010, 11(11): 1014-1022.
[2]	Gao WT, Kumar S, Lotze MT, et al. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity[J]. J Immunol, 2003, 170(1): 107-113.
[3]	Xu WD, Zhao Y, Liu Y. Insights into IL-37, the role in autoimmune diseases[J]. Autoimmun Rev, 2015, 14(12): 1170-1175.
[4]	Quirk S, Agrawal DK. Immunobiology of IL-37: mechanism of action and clinical perspectives[J]. Expert Rev Clin Immunol, 2014, 10(12): 1703-1709.
[5]	Chen B, Huang K, Ye L, et al. Interleukin-37 is increased in ankylosing spondylitis patients and associated with disease activity[J]. J Transl Med, 2015, 13(13): 36-44.
[6]	Ding L, Hong X, Sun B, et al. IL-37 is associated with osteoarthritis disease activity and suppresses proinflammatory cytokines production in synovial cells[J/OL]. Sci Rep, 2017, 7(1): 11601. doi: 10.1038/s41598-017-11397-5.
[7]	Banchereau J, Pascual V, O’garra A. From IL-2 to IL-37: the expanding spectrum of anti-inflammatory cytokines[J]. Nat Immunol, 2012, 13(10): 925-931.
[8]	Zhao PW, Jiang WG, Wang L, et al. Plasma levels of IL-37 and correlation with TNF-α, IL-17A, and disease activity during DMARD treatment of rheumatoid arthritis[J/OL]. PLoS One, 2014, 9(5): e95346. doi: 10.1371/journal.pone.0095346.eCollection2014.
[9]	Liu L, Xue Y, Zhu YF, et al. Interleukin 37 limits monosodium urate crystal-induced innate immune responses in human and murine models of gout[J]. Arthritis Res Ther, 2016, 18(1): 268-282.
[10]	Zeng M, Dang W, Chen B, et al. IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response[J]. Clin Rheumatol, 2015, 35(9): 2251-2258.
[11]	Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family[J]. Eur Cytokine Netw, 2011, 22(3): 127-147.
[12]	Ellisdon AM, Nold-Petry CA, D’andrea L, et al. Homodimerization attenuates the anti-inflammatory activity of interleukin-37[J/OL]. Sci Immunol, 2017, 2(8):1548. doi：10.1126/sciimmunol.aaj1548.
[13]	Nold-Petry CA, Lo CY, Rudloff I, et al. IL-37 requires the receptors IL-18 Ralpha and IL-1R 8(SIGIRR)to carry out its multifaceted anti-inflammatory program upon innate signal transduction[J]. Nat Immunol, 2015, 16(4): 354-365.
[14]	Sharma S, Kulk N, Nold MF, et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinflammatory cytokines[J]. J Immunol, 2008, 180(8): 5477-5482.
[15]	Akdis M, Burgler S, Crameri R, et al. Interleukins, from 1 to 37, and interferon-gamma: receptors, functions, and roles in diseases[J]. J Allergy Clin Immunol, 2011, 127(3): 701-721.
[16]	Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease[J]. Immunology, 2010, 129(3): 311-321.
[17]	Zhang W, Cong XL, Qin YH, et al. IL-18 upregulates the production of key regulators of osteoclastogenesis from fibroblast-like synoviocytes in rheumatoid arthritis[J]. Inflammation, 2013, 36(1): 103-109.
[18]	Shao XT, Feng L, Gu LJ, et al. Expression of interleukin-18, IL-18BP, and IL-18R in serum, synovial fluid, and synovial tissue in patients with rheumatoid arthritis[J]. Clin Exp Med, 2009, 9(3): 215-221.
[19]	Chovanova L, Vlcek M, Krskova K, et al. Increased production of IL-6 and IL-17 in lipopolysaccharide-stimulated peripheral mononuclears from patients with rheumatoid arthritis[J]. Gen Physiol Biophys, 2013, 32(3): 395-404.
[20]	Yang LB, Zhang J, Tao JA, et al. Elevated serum levels of interleukin-37 are associated with inflammatory cytokines and disease activity in rheumatoid arthritis[J]. APMIS, 2015, 123(12): 1025-1031.
[21]	Song LJ, Wang YQ, Sui YM, et al. High interleukin-37 (IL-37) expression and increased mucin-domain containing-3 (TIM-3) on peripheral T cells in patients with rheumatoid arthritis[J]. Med Sci Monit, 2018, 8(24): 5660-5667.
[22]	Ragaba D, Mobasher S, Shabaan E. Elevated levels of IL-37 correlate with T cell activation status in rheumatoid arthritis patients[J]. Cytokine, 2019, 113(18): 305-310.
[23]	Xia LP, Shen H, Lu J. Elevated serum and synovial fluid levels of interleukin-37 in patients with rheumatoid arthritis: attenuated the production of inflammatory cytokines[J]. Cytokine, 2015, 76(2): 553-557.
[24]	Hahn M, Frey S, Hueber AJ. The novel interleukin-1 cytokine family members in inflammatory diseases[J]. Curr Opin Rheumatol, 2017, 29(2): 208-213.
[25]	Pei B, Xu S, Liu T, et al. Associations of the IL-1F7 gene polymorphisms with rheumatoid arthritis in Chinese Han population[J]. Int J Immunogenet, 2013, 40(3): 199-203.
[26]	Limón-Camacho L, Vargas-Rojas M, Vázquez-Mellado J, et al. In vivo peripheral blood proinflammatory T cells in patients with ankylosing spondylitis[J]. J Rheumatol, 2012, 39(4): 830-835.
[27]	Fawzy RM, Ganeb SS, Said EA, et al. Serum level of interleukin-37 and expression of its mRNA in ankylosing spondylitis patients：possible role in osteoporosis[J]. Egypt J Immunol, 2016, 23(1): 19-29.
[28]	Terkeltaub R. What makes gouty inflammation so variable？[J/OL]. BMC Med, 2017, 15(1): 158.doi：10.1186/s12916-017-0922-s.
[29]	Klein-Wieringa IR, Lange-Brokaar LB, Yusuf E, et al. Inflammatory cells in patients with endstage knee osteoarthritis：a comparison between the synovium and the infrapatellar fat pad[J]. J Rheumatol, 2016, 43(4): 771–778.
[30]	Berenbaum F. Osteoarthritis as an inflammatory disease(osteoarthritis is not osteoarthrosis！)[J]．Osteoarthritis Cartilage, 2013, 21(1): 16-21.
[31]	Weber A, Chan P, Wen C. Do immune cells Lead the way in subchondral bone disturbance in osteoarthritis？[J]. Prog Biophys Mol Biol, 2017, 12(17): 30181-30185. doi: 10.1016/j.pbiomolbio.
[32]	Kapoor M, Martel-Pelletier J, Lajeunesse D, et al. Role of proinflammatory cytokines in the pathophysiology of osteoarthritis[J]. Nat Rev Rheumatol, 2011, 7(1): 33-42.
[33]	Daheshia M, Yao JQ. The interleukin 1 beta pathway in the pathogenesis of osteoarthritis[J]. Rheumatology, 2008, 35(12): 2306-2312.
[34]	van Geffen EW, van Caam A, Schreurs W, et al. IL-37 diminishes proteoglycan loss in human OA cartilage: donor-specific Link between IL-37 and MMP-3[J]. Osteoarthritis Cartilage, 2019, 27(1): 31440-31447.
[35]	Cavalli G, Koenders M, Kalabokis V, et al. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation[J]. Rheumatology, 2016, 55(12): 2220-2229.
[36]	Jy Y, Fau-An YJ, An JM, et al. Mutation analysis of the Smad3 gene in human osteoarthritis[J]. Eur J Hum Gene, 2003, 11(9): 714-717.
[37]	Grimsby S, Jaensson H, Dubrovska A, et al. Proteomics-based identification of proteins interacting with Smad3: SREBP-2 forms acomplex with Smad3 and inhibits its transcriptional activity[J]. FEBS Lett, 2004, 577(1-2):93-100.

Please choose a citation manager

Content to export